Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 13,595 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatologic Disorders Clear all
Completed Phase 2 Interventional Results available

Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

NCT00563290
View directory record Official record
Conditions
Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia
Interventions
dasatinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbus, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 23, 2026, 2:24 AM EDT
Completed No phase listed Observational

Near Infrared/ Ultrasound Dual Modal Imaging for Breast Cancer Diagnosis

NCT00499980
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 12, 2007 · Synced Oct 23, 2026, 2:24 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients

NCT05074290
View directory record Official record
Conditions
Breast Cancer
Interventions
Epidiferphane, Taxane Chemotherapy
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 23, 2026, 2:24 AM EDT
Active, not recruiting Phase 2 Interventional Results available

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

NCT06001762
View directory record Official record
Conditions
Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
Interventions
Abemaciclib, Tamoxifen, Anastrozole, Letrozole, Exemestane, LHRH Agonist
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Stamford, Connecticut • Brewer, Maine • Scarborough, Maine + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 23, 2026, 2:24 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Effects of Treatments on Atopic Dermatitis

NCT01631617
View directory record Official record
Conditions
Eczema, Dermatitis, Skin Diseases, Genetic, Dermatitis, Atopic, Skin Diseases
Interventions
Trimethoprim/sulfamethoxazole (TMP/SMZ), Cephalexin, Doxycycline, Sodium hypochlorite, Placebo capsules, Placebo Sodium hypochlorite
Drug · Other
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
2 Years to 50 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 2:24 AM EDT
Completed No phase listed Observational

Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk

NCT00735150
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
questionnaire, interview
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 39 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2010 · Synced Oct 23, 2026, 2:24 AM EDT
Terminated Phase 4 Interventional Results available

Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM)

NCT04625517
View directory record Official record
Conditions
Breast Cancer
Interventions
Digital Mammography, Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml
Procedure · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 23, 2026, 2:24 AM EDT
Not listed Phase 2 Interventional

Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer

NCT00027989
View directory record Official record
Conditions
Breast Cancer
Interventions
gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
Pharmatech Oncology
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
6
States / cities
Montgomery, Alabama • West Covina, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 2 Interventional

Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer

NCT00079118
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, irinotecan hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
162
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 102 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis

NCT01826201
View directory record Official record
Conditions
Psoriasis
Interventions
MOL4239, Placebo
Drug
Lead sponsor
Moleculin, LLC
Industry
Eligibility
18 Years to 72 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Miami, Florida • Fridley, Minnesota • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Early Phase 1 Interventional

Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations

NCT02646319
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma, Endometrial Carcinoma, Malignant Uterine Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Malignant Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage III Bladder Cancer, Stage III Prostate Cancer, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIA Cervical Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Breast Cancer, Stage IIIB Cervical Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Breast Cancer, Stage IIIC Ovarian Cancer, Stage IV Breast Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IVA Bladder Cancer, Stage IVA Cervical Cancer, Stage IVB Bladder Cancer, Stage IVB Cervical Cancer
Interventions
Laboratory Biomarker Analysis, Nanoparticle Albumin-Bound Rapamycin, Quality-of-Life Assessment
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 23, 2026, 2:24 AM EDT
Active, not recruiting Phase 2 Interventional

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267
View directory record Official record
Conditions
Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
Interventions
Entrectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
48
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

NCT00005798
View directory record Official record
Conditions
Breast Cancer
Interventions
Carboplatin, Cyclophosphamide, Thiotepa
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 64 Years · Female only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2007
U.S. locations
3
States / cities
Daytona Beach, Florida • Fort Myers, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 23, 2026, 2:24 AM EDT
Terminated Phase 2 Interventional Results available

Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

NCT00003509
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population

NCT01137032
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
Pandel Cream 0.1%
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
3 Months and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
3
States / cities
Omaha, Nebraska • Hilton Head Island, South Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 23, 2026, 2:24 AM EDT
Recruiting Phase 3 Interventional

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

NCT06500481
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Involved-Field Radiation Therapy, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Craniospinal Irradiation, Quality-of-Life Assessment
Procedure · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
58
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Encinitas, California + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 4 Interventional

Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents

NCT03279328
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Topical Steroid Ointment, Vaseline, Skin Barrier Moisturier
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 23, 2026, 2:24 AM EDT
Completed No phase listed Observational

A Pilot Study of the Envision® Surface

NCT00405834
View directory record Official record
Conditions
Pressure Ulcers
Interventions
Envision® Patient Support System
Device
Lead sponsor
Hill-Rom
Industry
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2008 · Synced Oct 23, 2026, 2:24 AM EDT
Terminated Phase 3 Interventional

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

NCT00522834
View directory record Official record
Conditions
Melanoma
Interventions
Elesclomol (STA-4783), Paclitaxel
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
61
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

NCT01384630
View directory record Official record
Conditions
Psoriasis
Interventions
RA-18C3
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Owensboro, Kentucky • Ann Arbor, Michigan • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 23, 2026, 2:24 AM EDT
Not yet recruiting Phase 3 Interventional

A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]

NCT07840287
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
Interventions
Enpatoran
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 76 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Billerica, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 2:24 AM EDT
Not listed Not applicable Interventional

Ultrasound vs. Predetermined Distance Techniques for Paravertebral Nerve Block in Patients Having Breast Surgery

NCT01217593
View directory record Official record
Conditions
Mastectomy, Breast Neoplasms
Interventions
ultrasound, predetermined distance
Procedure
Lead sponsor
Ochsner Health System
Other
Eligibility
25 Years to 85 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 21, 2014 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

AGN-199201 for the Treatment of Erythema With Rosacea

NCT01735201
View directory record Official record
Conditions
Rosacea, Erythema
Interventions
AGN-199201 Dose A, AGN-199201 Dose B, AGN-199201 Dose C, AGN-199201 Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 23, 2026, 2:24 AM EDT
Completed Phase 1 Interventional

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

NCT03195699
View directory record Official record
Conditions
Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Melanoma, Advanced Cancer
Interventions
TTI-101
Drug
Lead sponsor
Tvardi Therapeutics, Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 23, 2026, 2:24 AM EDT